Index RUT
P/E -
EPS (ttm) -2.77
Insider Own 5.93%
Shs Outstand 95.93M
Perf Week 3.39%
Market Cap 64.34M
Forward P/E -
EPS next Y -1.16
Insider Trans 12.35%
Shs Float 95.88M
Perf Month -51.06%
Income -290.25M
PEG -
EPS next Q -0.49
Inst Own 98.03%
Short Float / Ratio 8.51% / 2.07
Perf Quarter -59.79%
Sales 4.54M
P/S 14.17
EPS this Y -11.24%
Inst Trans -0.22%
Short Interest 8.16M
Perf Half Y -61.51%
Book/sh -0.50
P/B -
EPS next Y 53.31%
ROA -104.20%
Target Price 9.46
Perf Year -86.74%
Cash/sh 1.01
P/C 0.63
EPS next 5Y -
ROE -425.97%
52W Range 0.20 - 5.64
Perf YTD -80.75%
Dividend -
P/FCF -
EPS past 5Y 10.97%
ROI -
52W High -88.81%
Beta 0.70
Dividend % -
Quick Ratio 1.42
Sales past 5Y 42.51%
Gross Margin -390.18%
52W Low 217.88%
ATR 0.13
Employees 334
Current Ratio 1.50
Sales Q/Q -52.05%
Oper. Margin -6417.09%
RSI (14) 41.58
Volatility 15.86% 24.17%
Optionable Yes
Debt/Eq -
EPS Q/Q 20.10%
Profit Margin -6390.31%
Rel Volume 0.37
Prev Close 0.70
Shortable Yes
LT Debt/Eq -
Earnings Nov 01 BMO
Payout -
Avg Volume 3.94M
Price 0.63
Recom 2.71
SMA20 0.73%
SMA50 -43.33%
SMA200 -68.54%
Volume 1,456,351
Change -9.85%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-09-23 Downgrade
Mizuho
Buy → Neutral
$31 → $1
Nov-09-23 Downgrade
H.C. Wainwright
Buy → Neutral
Nov-09-23 Downgrade
Evercore ISI
Outperform → In-line
Jul-20-22 Downgrade
Citigroup
Neutral → Sell
$8 → $3
Jul-13-22 Downgrade
Stifel
Buy → Hold
$16 → $5
Jul-13-22 Downgrade
JP Morgan
Overweight → Neutral
$10
May-10-22 Downgrade
Citigroup
Buy → Neutral
$15 → $8
May-13-21 Upgrade
JP Morgan
Neutral → Overweight
$23 → $29
Dec-09-20 Downgrade
Citigroup
Buy → Neutral
$20 → $27
Dec-08-20 Reiterated
H.C. Wainwright
Buy
$28 → $31
Nov-10-20 Reiterated
H.C. Wainwright
Buy
$26 → $28
Jun-30-20 Initiated
Evercore ISI
Outperform
Jun-15-20 Initiated
H.C. Wainwright
Buy
$25
Apr-23-20 Upgrade
Citigroup
Neutral → Buy
$14
Nov-08-19 Downgrade
JP Morgan
Overweight → Neutral
$43 → $22
Sep-27-19 Downgrade
Goldman
Neutral → Sell
$14 → $9
Sep-16-19 Downgrade
Jefferies
Buy → Hold
$32 → $15
Jun-04-19 Upgrade
Citigroup
Sell → Neutral
$23 → $24
May-30-19 Initiated
ROTH Capital
Buy
May-23-19 Initiated
Stifel
Buy
Show Previous Ratings
Dec-01-23 04:01PM
Nov-29-23 06:05PM
Nov-24-23 12:29PM
Nov-22-23 04:01PM
09:14AM
04:01PM
Loading…
Nov-10-23 04:01PM
Nov-09-23 08:23AM
06:40AM
Nov-08-23 05:35PM
Nov-05-23 12:50PM
Nov-02-23 05:42AM
02:25AM
(Thomson Reuters StreetEvents)
Nov-01-23 08:35AM
(Associated Press Finance)
08:30AM
Oct-06-23 04:01PM
09:19AM
Loading…
Sep-21-23 09:19AM
Sep-19-23 04:01PM
Sep-01-23 04:01PM
Aug-31-23 04:01PM
Aug-13-23 10:44AM
Aug-08-23 05:30PM
04:18PM
04:01PM
Aug-04-23 04:01PM
Aug-01-23 04:01PM
Jul-31-23 04:01PM
Jul-29-23 11:07AM
Jul-17-23 07:29AM
Jul-07-23 04:01PM
Jun-16-23 06:05AM
04:01PM
Loading…
Jun-07-23 04:01PM
Jun-05-23 09:00AM
Jun-02-23 04:01PM
May-18-23 07:09AM
May-08-23 05:15PM
04:12PM
04:01PM
May-07-23 08:59AM
May-05-23 04:01PM
May-01-23 04:01PM
Apr-16-23 12:08PM
Mar-31-23 04:01PM
Mar-24-23 09:35AM
Mar-03-23 04:01PM
09:40AM
Mar-01-23 04:01PM
Feb-21-23 04:01PM
Feb-15-23 06:58AM
Feb-08-23 05:15PM
04:01PM
06:00AM
Feb-06-23 08:00AM
Feb-03-23 04:01PM
Jan-13-23 04:01PM
Jan-04-23 04:01PM
Dec-24-22 10:07AM
Dec-20-22 04:33PM
Dec-19-22 08:00AM
07:00AM
Dec-15-22 04:01PM
Dec-12-22 10:00AM
Dec-02-22 04:01PM
Nov-23-22 08:00AM
Nov-22-22 05:03AM
Nov-10-22 05:52AM
(Simply Wall St.) +23.97%
Nov-09-22 04:01PM
Nov-08-22 05:15PM
04:01PM
Nov-04-22 04:01PM
Nov-01-22 04:05PM
Oct-26-22 02:01AM
Oct-14-22 07:08AM
Oct-13-22 12:51PM
Oct-10-22 04:01PM
Oct-07-22 10:01AM
Oct-06-22 01:36PM
Sep-30-22 08:59AM
Sep-29-22 11:09AM
07:30AM
Sep-28-22 04:01PM
01:47PM
Sep-27-22 10:13AM
Sep-21-22 06:32PM
Sep-13-22 03:45PM
08:44AM
Sep-07-22 01:31PM
01:15PM
Sep-06-22 09:26AM
Sep-05-22 10:21AM
Aug-31-22 04:01PM
12:12PM
Aug-25-22 11:52AM
Aug-24-22 06:03PM
(American City Business Journals) +8.75%
Aug-23-22 01:53PM
Aug-16-22 10:09AM
Aug-15-22 09:55AM
Aug-11-22 01:13PM
Aug-09-22 03:01PM
Aug-08-22 05:35PM
04:01PM
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Touchon Pascal President and CEO Nov 16 Sale 0.39 20,409 7,939 655,496 Nov 20 05:31 PM Joshi Manher EVP, Chief Medical Officer Nov 16 Sale 0.39 12,287 4,780 171,284 Nov 20 05:30 PM Hyllengren Eric J SVP, CFO Nov 16 Sale 0.39 11,958 4,652 205,998 Nov 20 05:29 PM Nguyen AnhCo EVP, Chief Sci. & Tech Officer Nov 16 Sale 0.39 8,856 3,445 277,143 Nov 20 05:31 PM Murugan Amar EVP, Chief Legal Officer Nov 16 Sale 0.39 8,307 3,231 257,084 Nov 20 05:30 PM Henrich Jill EVP, Global Head RA & Quality Nov 16 Sale 0.39 3,267 1,271 104,424 Nov 20 05:29 PM Gallagher Carol Giltner Director Nov 14 Buy 0.31 90,980 28,186 459,418 Nov 15 05:07 PM Gallagher Carol Giltner Director Nov 13 Buy 0.22 179,020 40,029 368,438 Nov 15 05:07 PM DOBMEIER ERIC Director Nov 10 Buy 0.23 446,825 101,340 563,325 Nov 14 06:27 PM HEIDEN WILLIAM K Director Nov 10 Buy 0.25 100,000 25,330 209,000 Nov 14 06:29 PM Touchon Pascal President and CEO Aug 16 Sale 1.65 30,766 50,835 675,905 Aug 18 06:25 PM Nguyen AnhCo EVP, Chief Sci. & Tech Officer Aug 16 Sale 1.65 15,126 24,997 285,999 Aug 18 06:25 PM Murugan Amar EVP, Chief Legal Officer Aug 16 Sale 1.65 8,672 14,330 265,391 Aug 18 06:25 PM Hyllengren Eric J SVP, CFO Aug 16 Sale 1.65 8,186 13,527 217,956 Aug 18 06:25 PM Joshi Manher EVP, Chief Medical Officer Aug 16 Sale 1.65 6,975 11,526 183,571 Aug 18 06:25 PM Henrich Jill EVP, Global Head RA & Quality Aug 16 Sale 1.65 3,346 5,531 107,691 Aug 18 06:25 PM Touchon Pascal President and CEO Jun 27 Sale 1.66 14,291 23,723 706,671 Jun 29 04:15 PM Touchon Pascal President and CEO May 16 Sale 2.04 29,766 60,633 720,962 May 18 08:17 PM Banard Charlene A. EVP, Chief Technical Officer May 16 Sale 2.04 19,040 38,784 276,010 May 18 08:17 PM Murugan Amar EVP, Chief Legal Officer May 16 Sale 2.04 8,389 17,089 270,945 May 18 08:17 PM Hyllengren Eric J SVP, CFO May 16 Sale 2.04 7,918 16,131 226,142 May 18 08:17 PM Touchon Pascal President and CEO Mar 02 Sale 3.63 15,679 56,868 750,728 Mar 06 06:49 PM Koppikar Utpal Chief Financial Officer Mar 02 Sale 3.63 6,871 24,921 181,978 Mar 06 06:47 PM Dupont Jakob EVP, Head of R&D Mar 02 Sale 3.63 5,074 18,403 290,794 Mar 06 06:46 PM Murugan Amar SVP, GC & Secretary Mar 02 Sale 3.63 4,221 15,310 279,334 Mar 06 06:48 PM Koppikar Utpal Chief Financial Officer Feb 07 Sale 5.46 2,485 13,568 188,849 Feb 09 05:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite